biochemical autoantibody (p=0.003, Kaplan-Meier log rank test), although the genotype was unrelated to disease development among those with more advanced autoimmunity. Subsequent analysis of Znt8 antibodies revealed that this antibody was significantly associated with development of diabetes (p=0.047, Fisher’s Exact test) but the DR3/DR4 genotype association with progression to clinical diabetes tended to remain after exclusion of these cases.  

**Conclusion:** These results suggest that autoimmunity spreading associated with the high-risk HLA class II genotype is taking place in subjects positive for only one biochemical autoantibody although such spreading cannot be detected by current autoantibody tests.  

**Supported by:** JDRF Academy of Finland, Sigrid Juselius Foundation

### 352

**HLA-haplotypes, autoantibodies to beta cells: their role in the prediction of type 1 diabetes**  
E.V. Titovich, T.L. Kuraeva, S.A. Prokof’ev, V.A. Peterkova, I.I. Dedov; The Institute of Pediatric Endocrinology, Endocrinology Research Center, Moscow

**Background and aims:** Risk of Type 1 Diabetes (T1D) development in mainly defined by susceptible haplotypes of HLA DR and DQ genes carriage and specific autoantibodies (Ab) presence. Prediction of early preclinical stage of T1DM.

**Materials and methods:** Predisposing and protective haplotypes (HLA-DRB1, genes DQ) together with immunological markers (ICA, GADA, IA2) have been studied in 143 discordant families, in normal siblings (N=171; mean age - 11.9±5.8 years). Simultaneously HLA-genotyping was performed in 599 patients with Type 1 Diabetes (mean age - 7.5±6.2 years). Control group included 200 individuals.

**Results:** During the trial the haplotypes susceptible to T1D [DRB1*4-DQA1*501-DQB1*02 (OR=4.7); DRB1*17-DQA1*501-DQB1*201 (OR=2.7); DRB1*4-DQA1*501-DQB1*301 (OR=4.0); DRB1*1-DQA1*101-DQB1*501 (OR=1.9); DRB1*16-DQA1*102-DQB1*502/4 (OR=2.4) and protective [DRB1*15-DQA1*102-DQB1*602/8 (OR=0.08); DRB1*11-DQA1*501-DQB1*301 (OR=0.14); DRB1*13-DQA1*103-DQB1* 602/8 (OR=0.16)] were defined in 599 T1D patients, belonging to Russian population. Analyzing of HLA haplotypes prevalence in patients’ families and in control group it was revealed that susceptible haplotypes incidence was lower in normal siblings [DRB1*4-DQA1*301-DQB1*302; DRB1*17-DQA1*501-DQB1*201] - 45.6% and 31%, comparing with patients - 61.5% and 51.7%, respectively (χ²=7.9, p<0.001; χ²=13.93, p<0.0001); though it was higher comparing with control group - 8.5% and 10%, respectively (χ² =66.7, p<0.0001; χ² =25.7, p=0.001). It should be noted that protective haplotypes [DRB1*15-DQA1*102-DQB1*602/8;DRB1*13-DQA1*103-DQB1*602/8] incidence was higher in normal siblings comparing with patients - 22.8% and 4.9%, respectively, (χ² =19.98, p<0.0001) and didn’t differ from the incidence in control group -22% (χ²=0.03, p=0.85). It is possible to suggest that protective haplotypes play their role in disease susceptibility lowering disease incidence among normal siblings. Three risk groups were selected in siblings of patients with T1D, considering that heterozygosis according to haplotypes [DQA1*0501-DQB1*0201 (DQ2) and DQA1*0301-DQB1*0302 (DQ8)] specifies the highest risk of T1D development. The high genetic risk group (DQ2/DQ8) included 13.5%, moderate risk group (DQ2/X, DQ8/X - 59.7% and low risk group (X/X) - 36.8%, where X is any haplotype, besides DQ2/DQ8. Incidence rate of two and three Ab types in high risk group was higher than in moderate and low risk groups (26.1%, 14.1%, 11.1% respectively; p<0.05; 8.7%, 2.4%, 0% respectively; p<0.05). In this case GAD was defined higher than in moderate and low risk groups (26,1%, 14,1%, 11,1% respectively; p<0.0001; χ²=31.5, p<0.0001). It should be noted that protective haplotypes of HLA DR and DQ genes carriage and specific autoantibodies (Ab) presence. Prediction of early preclinical stage of T1DM.  

### 353

**Role of the repair enzyme PIMT in type 1 diabetes: studies in patients, dogs with diabetes and PIMT knock-out mice**  
J.C. Wiebe1, L. López-Ríos2, Y. Brito-Casillas3, C. Melián4, A. Arin-Martínez5, E. González1, A. Tugores6, M. Boronat7, J. Nóvoa3, A.M. Wagner1

1Endocrinology Dept, Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria (CHUIMI); 2Ciencias Médicas y Quirúrgicas, Universidad de Las Palmas de Gran Canaria; 3Endocrinology Dept, CHUIMI, 4Hospital Clínico Universitario, Universidad de Las Palmas de Gran Canaria, 5Bioquímica, Biología Molecular, Fisiología, Genética e Inmunología Dept., 6Research Unit, CHUIMI, 7Ciencias Médicas y Quirúrgicas Dept, Universidad de Las Palmas de Gran Canaria, Spain.

**Background and aims:** Post-translational protein modifications may create new antigenic epitopes and elicit autoimmune responses. Protein isomerization (ZnT8) has been associated with type 1 diabetes (T1D) development. As Znt8 antibodies were detected in 82% cases and only 18,2% from examined individuals with groups of moderate and low genetic risk (65%; 37,9%; 18%, respectively; significantly more often in the group with DQ2/DQ8 genotype, comparing ly; p>0.05; 8,7%, 2,4%, 0% respectively, p<0.05). In this case GAD was defined higher than in moderate and low risk groups (26,1%, 14,1%, 11,1% respectively; p<0.0001; χ²=31.5, p<0.0001). It should be noted that protective haplotypes absence doesn’t completely protect from disease development.

**Supported by:** JDRF, Academy of Finland, Sigrid Juselius Foundation

**Role of the repair enzyme PIMT in type 1 diabetes: studies in patients, dogs with diabetes and PIMT knock-out mice**

**Results:** Blood samples are available from 82 participants, though only 52 (50% women) have been analysed. Median [range] PIMT1 expression tended to be reduced in the 19 T1D (3.03 [0.49-16]; p=0.083) as compared to the 28 controls (6.57 [0.81-32.67]), whereas no difference was found in the small group (N=5) with T2D (<5 years since diagnosis and no complications) and healthy subjects matched for age and gender were selected. Samples from diabetic and non-diabetic dogs were collected. The expression of PCMT1 mRNA was assayed by qPCR. Transcription levels were normalized to β-actin by comparative Ct. Red blood cells were filtered and lysed. The cytosol was separated and depleted of haemoglobin and Western Blot for PIMT was performed. Heterozygous PIMT+/− mice were crossed and their offspring, genotyped. PIMT knock-out mice were compared with their littermates at 5-6 weeks of age. The data obtained confirmed once more once more, that the Pcmt gene seems to have a dose effect on glucose tolerance in mice. Ongoing experiments and sample collection should add to these results.  

**Conclusion:** PCMT1 mRNA expression was normal, both in patients with T1D and in dogs with diabetes. However, preliminary results point towards possible differences in protein expression, suggesting that it might be post-transcriptionally regulated. Furthermore, although sample sizes are still small, the Pcmt gene seems to have a dose effect on glucose tolerance in mice. Ongoing experiments and sample collection should add to these results.  

**Supported by:** EFSDB, ISCIII, FUNCIS, ACISIS, ULPGC

**Role of the repair enzyme PIMT in type 1 diabetes: studies in patients, dogs with diabetes and PIMT knock-out mice**

**Results:** Blood samples are available from 82 participants, though only 52 (50% women) have been analysed. Median [range] PIMT1 expression tended to be reduced in the 19 T1D (3.03 [0.49-16]; p=0.083) as compared to the 28 controls (6.57 [0.81-32.67]), whereas no difference was found in the small group (N=5) with T2D (<5 years since diagnosis and no complications) and healthy subjects matched for age and gender were selected. Samples from diabetic and non-diabetic dogs were collected. The expression of PCMT1 mRNA was assayed by qPCR. Transcription levels were normalized to β-actin by comparative Ct. Red blood cells were filtered and lysed. The cytosol was separated and depleted of haemoglobin and Western Blot for PIMT was performed. Heterozygous PIMT+/− mice were crossed and their offspring, genotyped. PIMT knock-out mice were compared with their littermates at 5-6 weeks of age. The data obtained confirmed once more once more, that the Pcmt gene seems to have a dose effect on glucose tolerance in mice. Ongoing experiments and sample collection should add to these results.  

**Conclusion:** PCMT1 mRNA expression was normal, both in patients with T1D and in dogs with diabetes. However, preliminary results point towards possible differences in protein expression, suggesting that it might be post-transcriptionally regulated. Furthermore, although sample sizes are still small, the Pcmt gene seems to have a dose effect on glucose tolerance in mice. Ongoing experiments and sample collection should add to these results.  

**Supported by:** EFSDB, ISCIII, FUNCIS, ACISIS, ULPGC